What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Axonius acquired healthcare and medical-device-security company Cynerio on July 29, 2025, in a cash-and-stock transaction officially valued at more than $100 million. Axios later reported the purchase price as $109 million, but Axonius has not publicly confirmed the precise figure or disclosed the cash-and-stock split.
The deal gives Axonius specialized visibility into connected medical devices while extending Cynerio’s capabilities across Axonius’s broader asset-intelligence platform. The combination is aimed at hospitals first, but its longer-term significance is wider: Axonius is using the acquisition as a foundation for security coverage across healthcare, IoT, operational technology and other cyber-physical environments.
As an Amazon Associate I earn from qualifying purchases.
The deal in brief
| Item | Verified detail |
|---|---|
| Announcement | July 29, 2025 |
| Buyer | Axonius |
| Target | Cynerio, an Israeli healthcare and medical-device-security company |
| Consideration | Cash and stock |
| Official value | More than $100 million |
| Reported exact value | $109 million, according to Axios |
| Cynerio adviser | Piper Sandler |
| Leadership | Leon Lerman became an Axonius senior vice president; Daniel Brodie joined the Office of the CTO |
Axonius described Cynerio as its first acquisition. The company’s official announcement did not disclose the exact purchase price, cash-and-stock allocation, earn-outs, retention arrangements or integration costs.
Why medical devices are a difficult security problem
Hospitals do not operate ordinary corporate networks. Their environments combine administrative IT with infusion pumps, imaging systems, ventilators, patient monitors, laboratory equipment and other connected clinical devices. Many devices cannot run conventional endpoint agents, use legacy operating systems or require manufacturer approval before they can be patched.
#1 Best Overall
Taking a vulnerable device offline may be clinically unacceptable. A vulnerability’s practical importance therefore depends on more than its CVSS score. Security teams also need to know the device’s clinical role, location, network exposure, ownership, available compensating controls and potential effect on patient care.
Responsibility is commonly divided among the CISO’s team, IT, clinical engineering, facilities, device manufacturers and maintenance providers. That makes incomplete inventories and stale ownership records operational risks, not merely documentation problems.
What Cynerio brought to Axonius
Cynerio specialized in healthcare IoT and medical-device security. Its capabilities included:
Recommended Free Tools
- Identifying and classifying connected medical devices.
- Monitoring device activity and network behavior.
- Providing clinical and operational context for device risk.
- Identifying vulnerabilities and exposed electronic protected health information.
- Supporting microsegmentation and segmentation validation.
- Helping hospitals investigate and mitigate ransomware exposure and other cyberattacks.
Cynerio was not simply an endpoint-security product that hospitals install on every device. Its value was largely in passive visibility, medical-device context and controls suitable for equipment that may be unsafe or impossible to scan, patch or interrupt like a standard laptop.
What Axonius contributed
Axonius already aggregated asset information from enterprise systems and connected it to exposure-management and remediation workflows. The strategic thesis was straightforward: Axonius supplied the broad asset-intelligence layer, while Cynerio supplied medical-device and clinical-environment specialization.
That combination is intended to give security, IT and biomedical teams a more unified record of assets across traditional IT, IoT, operational technology and medical environments. It can also connect a device’s identity and risk to ownership, network placement, tickets and policy controls.
The acquisition should therefore be understood as both a healthcare-market entry and a platform expansion—not merely as a small technology tuck-in.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchHow Axonius for Healthcare works
Axonius’s documentation says its healthcare offering uses passive network monitoring to discover IoT, OT and medical devices. An Axonius Network Inspector appliance connects to a core-switch SPAN port, receives mirrored network traffic and analyzes it using deep packet inspection. This approach is designed to avoid disruptive active probing of sensitive clinical equipment.
Rank #3
The resulting information is presented through dedicated workspaces, including:
- IoT/OT Discovery.
- Medical Devices Management.
- Risk and vulnerability views.
- Compliance and segmentation-validation workflows.
According to the Medical Devices Management Workspace documentation, teams can view device counts, manufacturers, categories, critical vulnerabilities, risk levels and network placement. The intended audience includes both cybersecurity personnel and clinical-engineering or biomedical teams.
Coverage still depends on deployment quality. An incomplete SPAN-port configuration, limited network visibility, unusual device behavior or inaccurate source data can result in an incomplete or misclassified inventory.
Free tools Windows power users keep installed
One-click scans. No signup required.
From Cynerio to a broader cyber-physical strategy
Axonius launched Axonius for Healthcare on October 22, 2025. The offering combined medical-device visibility with IoT and OT discovery, vulnerability context, governance, workflow automation and compliance reporting.
In 2026, Axonius broadened the direction into Axonius Cyber-Physical Assets, extending the acquired expertise beyond hospitals to manufacturing, utilities, energy and critical infrastructure. A later platform update described continued development across IT, IoT and OT.
That evolution matters because Axonius is no longer presenting Cynerio primarily as an unchanged standalone medical-device-security brand. The acquired capabilities are being incorporated into a wider asset-intelligence and cyber-physical-security strategy.
What the acquisition means for hospitals
Potential benefits
- A correlated asset model spanning enterprise IT and clinical devices.
- Passive discovery for equipment that cannot support standard agents.
- Improved coordination between security and biomedical engineering.
- More useful prioritization based on device identity, location, clinical role and network exposure.
- Continuous validation of segmentation policies.
- Workflows that connect findings to ticketing, network controls, vulnerability management and service management.
Important limitations
Discovery is not remediation. Identifying a vulnerable infusion pump does not patch it, make a manufacturer issue a fix or prove that patient-care risk has been eliminated. Passive monitoring may reveal a device and its exposure without providing every control required for prevention, segmentation enforcement or incident response.
Hospitals should also account for implementation effort, network-appliance requirements, data architecture, regional hosting, protected-health-information handling, integration permissions and possible overlap with existing NAC, SIEM, vulnerability-management, CMMS or medical-device-security tools.
Best Value
Questions buyers should ask
- Discovery: Can the platform identify unmanaged, legacy and specialized devices without agents?
- Clinical context: Can it distinguish a high-impact clinical device from a lower-risk IoT asset?
- Vulnerability analysis: Does it connect findings to firmware, manufacturer guidance, end-of-support status, reachability and compensating controls?
- Segmentation: Can it continuously detect when a device appears on an unauthorized VLAN or network segment?
- Workflow: Can findings be assigned to security, networking, biomedical engineering or a device manufacturer and tracked to completion?
- Data handling: Where is information processed and stored, and what regional or regulatory requirements apply?
- Integration: What existing tools become redundant, and what integrations require additional services or licensing?
- Continuity: How are monitoring, containment and remediation performed without interrupting clinical operations?
What remains undisclosed
Several commercially important details are not public. Axonius has not disclosed the definitive purchase price beyond “more than $100 million,” the cash-and-stock split, earn-outs, retention arrangements, Cynerio’s revenue contribution, integration costs or detailed customer-migration terms. Axonius also has not publicly listed standard pricing for its healthcare offering in the cited materials.
Existing Cynerio customers should confirm contract continuity, support ownership, product naming, migration requirements and roadmap commitments directly with Axonius. They should not assume that every standalone Cynerio capability, commercial term or support process remains unchanged.
Why the transaction matters to the cybersecurity market
The acquisition reflects a broader shift toward treating asset inventory as a prerequisite for exposure management. It also shows why specialized healthcare-security capabilities can become valuable acquisition targets when they can be connected to a larger enterprise platform.
For hospitals, the market is moving away from treating medical-device security as an isolated compliance task. The more useful question is whether a security platform can translate device discovery into clinically informed action: identify the asset, understand its role, validate its exposure, assign ownership, apply a safe mitigation and confirm that risk has been reduced.
For vendors and investors, the deal points toward convergence between enterprise IT security, IoT, OT and medical-device security. Axonius’s later cyber-physical-assets strategy supports that interpretation, although it should not be read as proof that the acquisition alone created a complete cyber-physical-security business.
Bottom line
Axonius bought Cynerio on July 29, 2025, in a cash-and-stock transaction officially worth more than $100 million; Axios reported the value as $109 million. Cynerio added medical-device discovery and clinical-environment expertise to Axonius’s broader asset-intelligence platform.
The deal’s success depends on execution. Axonius must preserve the clinical context that made Cynerio useful while delivering unified workflows across IT, medical devices and other cyber-physical assets. For hospitals, the acquisition may reduce fragmented inventories and improve risk coordination—but visibility alone does not replace patching, segmentation, manufacturer support or careful clinical-change management.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
